Micronomicin sulfate

The main ingredients of this product are: chloramphenicol sulfate. Molecular formula: C20H41N5O75/2H2SO4 Molecular weight: 708.76

This product cannot be used with dextran, uric acid, furosemide, etc.

Micromycin sulfate. Its chemical name is: O-2-amino-2,3,4,5-tetradeoxy-5-(methylamino)-2-D-erythro-hexopyranosyl-(1rarr;4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-b-L-arabinopyranosyl-(1rarr;6)-2-deoxy-D-streptamine sulfate.

1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used with other aminoglycosides or when applied topically or systemically one after the other. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used topically or systemically with cephalothin. 4 This product should not be used in combination with polymyxins, or applied topically or systemically in sequence, because it can increase nephrotoxicity and neuromuscular blocking effects, the latter of which can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5 This product should not be used in combination with other nephrotoxic or ototoxic drugs, or applied sequentially, so as not to aggravate nephrotoxicity or ototoxicity. 6 This product should not be used in combination with amphotericin B, cephalothin sodium, nitrofurantoin sodium, sulfadiazine sodium and tetracycline hydrochloride (all of the above are injections), because incompatibility may occur. 7 This product can often achieve synergistic effects when used in combination with beta-lactams (cephalosporins or penicillins). 8 This product mixed with beta-lactams (cephalosporins or penicillins) can lead to mutual inactivation, and must be dripped in separate bottles when used in combination.

Neomycin Sulfate

1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used with other aminoglycosides or when applied topically or systemically one after the other. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used topically or systemically with cephalothin. 4 This product should not be used in combination with polymyxins, or applied topically or systemically in sequence, because it can increase nephrotoxicity and neuromuscular blocking effects, the latter of which can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5 This product should not be used in combination with other nephrotoxic or ototoxic drugs, or applied sequentially, so as not to aggravate nephrotoxicity or ototoxicity. 6 This product should not be used in combination with amphotericin B, cephalothin sodium, nitrofurantoin sodium, sulfadiazine sodium and tetracycline hydrochloride (all of the above are injections), because incompatibility may occur. 7 This product can often achieve synergistic effects when used in combination with beta-lactams (cephalosporins or penicillins). 8 This product mixed with beta-lactams (cephalosporins or penicillins) can lead to mutual inactivation, and must be dripped in separate bottles when used in combination.